Laurus Labs Secures USFDA EIR for API Facility, Enhancing Global Compliance

Laurus Labs Limited has been issued the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Visakhapatnam, Andhra Pradesh. This achievement reaffirms the focus of the company on regulatory compliance as well as pharmaceutical manufacturing standards of quality.

 

Key Points:

This success reinforces Laurus Labs' position in the global pharma industry, underlining its quality and regulatory excellence commitment.

 

Source: CNBC TV18, Express Pharma, Business Standard